[go: up one dir, main page]

BRPI0606187A2 - comprimidos com capacidade de dispersão da substáncia do fármaco melhorada - Google Patents

comprimidos com capacidade de dispersão da substáncia do fármaco melhorada

Info

Publication number
BRPI0606187A2
BRPI0606187A2 BRPI0606187-7A BRPI0606187A BRPI0606187A2 BR PI0606187 A2 BRPI0606187 A2 BR PI0606187A2 BR PI0606187 A BRPI0606187 A BR PI0606187A BR PI0606187 A2 BRPI0606187 A2 BR PI0606187A2
Authority
BR
Brazil
Prior art keywords
drug substance
tablets
improved drug
vehicle
dispersibility
Prior art date
Application number
BRPI0606187-7A
Other languages
English (en)
Inventor
Nathalie Bernigal
Eric Garcia
Susanne Page
Joseph Tardio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36406213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0606187(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0606187A2 publication Critical patent/BRPI0606187A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPRIMIDOS COM CAPACIDADE DE DISPERSãO DA SUBSTáNCIA DO FáRMACO MELHORADA. A presente invenção refere-se a um método para a preparação de composições farmacêuticas na forma de comprimidos com capacidade de dispersão da substância do fármaco melhorada, o referido método sendo caracterizado pelo fato de que ele compreende as etapas de: a) preparar uma dispersão de pelo menos uma substância de fármaco farmaceuticamente ativa e pelo menos um tensoativo e/ou ligante em um líquido; b) preparar um veículo pela aglutinação a seco de um ou mais excipiente(s) incluindo pelo menos um veículo poroso; e c) granular por pulverização a dispersão preparada sob a) por cima do veículo preparado sob b) com a finalidade de ser obtido um produto granulado por pulverização.
BRPI0606187-7A 2005-02-25 2006-02-16 comprimidos com capacidade de dispersão da substáncia do fármaco melhorada BRPI0606187A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101458 2005-02-25
PCT/EP2006/001395 WO2006089674A2 (en) 2005-02-25 2006-02-16 Tablets with improved drug substance dispersibility

Publications (1)

Publication Number Publication Date
BRPI0606187A2 true BRPI0606187A2 (pt) 2009-06-09

Family

ID=36406213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606187-7A BRPI0606187A2 (pt) 2005-02-25 2006-02-16 comprimidos com capacidade de dispersão da substáncia do fármaco melhorada

Country Status (20)

Country Link
US (2) US20060193910A1 (pt)
EP (2) EP2281556A1 (pt)
JP (1) JP2008531509A (pt)
KR (1) KR20070094666A (pt)
CN (1) CN101128189A (pt)
AR (1) AR055561A1 (pt)
AU (1) AU2006218193A1 (pt)
BR (1) BRPI0606187A2 (pt)
CA (1) CA2598762A1 (pt)
CR (1) CR9292A (pt)
IL (1) IL185011A0 (pt)
MA (1) MA29268B1 (pt)
MX (1) MX2007009571A (pt)
NO (1) NO20074092L (pt)
NZ (1) NZ560232A (pt)
RU (1) RU2007129642A (pt)
TW (1) TW200640502A (pt)
UA (1) UA90708C2 (pt)
WO (1) WO2006089674A2 (pt)
ZA (1) ZA200706495B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20090196923A1 (en) * 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
EP2207533B1 (en) * 2007-10-10 2021-01-06 Avantor Performance Materials, LLC Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR20140002812A (ko) * 2009-01-23 2014-01-08 에프. 호프만-라 로슈 아게 알레글리타자르를 포함하는 약학 조성물
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
MX2012005347A (es) 2009-11-18 2012-08-03 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados.
CN102641302B (zh) * 2011-02-18 2016-01-20 上海张江中药现代制剂技术工程研究中心 一种提高中药提取物浸膏粉软化点的方法
RU2468789C1 (ru) * 2011-05-04 2012-12-10 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения атеросклероза
CN104784239B (zh) * 2015-04-28 2017-12-26 新乡医学院第一附属医院 一种快速溶出的珍菊降压片及其制备工艺
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
WO2017003137A1 (ko) * 2015-06-30 2017-01-05 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
EP3541385A4 (en) 2016-11-16 2020-06-24 Lundbeck La Jolla Research Center, Inc. PHARMACEUTICAL FORMULATIONS
US11142517B2 (en) 2016-11-16 2021-10-12 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
CN109701441B (zh) * 2018-12-16 2021-04-09 桂林理工大学 一种卵磷脂选择性改性高岭石的制备方法及其应用
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN111548218A (zh) * 2020-04-27 2020-08-18 上海应用技术大学 一种通用型花肥速释片及其制备方法和应用
US12296050B2 (en) * 2023-10-05 2025-05-13 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3118255B2 (ja) * 1991-01-30 2000-12-18 ザ ウエルカム ファウンデーション リミテッド 水分散性錠剤
PT533280E (pt) 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
ES2196079T3 (es) 1994-09-22 2003-12-16 Akzo Nobel Nv Procedimiento de fabricacion de unidades posologicas por medio de una granulacion por via humeda.
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
ATE285776T1 (de) 1996-12-02 2005-01-15 Merck Sharp & Dohme Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen
AU736042B2 (en) 1996-12-02 2001-07-26 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
GB9825242D0 (en) 1998-11-19 1999-01-13 Cambridge Advanced Tech Genetically modified plants with altered starch
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
HUP0200124A3 (en) 1999-02-24 2004-03-01 Hoffmann La Roche Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
HK1044942B (zh) 1999-02-24 2004-05-28 F. Hoffmann-La Roche Ag 3-苯基吡啶衍生物及其作為nk-1受體拮抗劑的應用
WO2000053772A1 (en) 1999-03-06 2000-09-14 Roche Diagnostics Gmbh Dna polymerase from pyrobaculum islandicum
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
DK1103545T3 (da) 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
EP1303490B1 (en) 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
DE60123661T2 (de) 2000-12-14 2007-08-16 F. Hoffmann-La Roche Ag Selbstemulgierende lipidmatrix (selm)
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
JP4146730B2 (ja) 2001-04-23 2008-09-10 エフ．ホフマン−ラ ロシュ アーゲー 良性前立腺肥大に対するｎｋ−１受容体拮抗薬の使用
WO2002092604A1 (en) 2001-05-14 2002-11-21 F. Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
MXPA04010537A (es) 2002-04-26 2005-01-25 Hoffmann La Roche Derivados de isoquinolina.
MXPA04011594A (es) 2002-05-29 2005-03-07 Hoffmann La Roche Derivados n-acilaminobenceno como inhibidores selectivos de monoamino oxidasa b.
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
PE20050077A1 (es) 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
EP1572666B1 (en) 2002-12-13 2006-08-09 F. Hoffmann-La Roche Ag 3h-quinazolin-4-one derivatives
HRP20050664A2 (en) 2003-01-31 2006-12-31 F. Hoffmann - La Roche Ag NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-A(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics

Also Published As

Publication number Publication date
AU2006218193A1 (en) 2006-08-31
NO20074092L (no) 2007-09-04
UA90708C2 (ru) 2010-05-25
MA29268B1 (fr) 2008-02-01
WO2006089674A2 (en) 2006-08-31
IL185011A0 (en) 2007-12-03
CN101128189A (zh) 2008-02-20
MX2007009571A (es) 2007-09-21
NZ560232A (en) 2010-11-26
KR20070094666A (ko) 2007-09-20
TW200640502A (en) 2006-12-01
CA2598762A1 (en) 2006-08-31
EP2281556A1 (en) 2011-02-09
RU2007129642A (ru) 2009-03-27
WO2006089674A3 (en) 2007-02-08
AR055561A1 (es) 2007-08-22
EP1855655A2 (en) 2007-11-21
US20090304795A1 (en) 2009-12-10
JP2008531509A (ja) 2008-08-14
CR9292A (es) 2010-04-21
US20060193910A1 (en) 2006-08-31
ZA200706495B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
BRPI0606187A2 (pt) comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
HRP20200046T1 (hr) Formulacije apiksabana
Agrawal et al. Hydrotropic solubilization of nimesulide for parenteral administration
Jain Solubilization of indomethacin using hydrotropes for aqueous injection
EP1893176B1 (de) Herstellung von festen lösungen schwerlöslicher wirkstoffe durch kurzzeitüberhitzung und schnelle trocknung
Sruti et al. Improvement in the dissolution rate and tableting properties of cefuroxime axetil by melt-granulated dispersion and surface adsorption
BRPI0608853A8 (pt) Composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
BRPI0812064B8 (pt) formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
UY32127A (es) Granulado conteniendo nicotina con muy reducida o nula producción de polvo en procesos donde se utilice y procedimientos de preparación
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
DK1719503T3 (da) Anvendelse af stivelse med fraspaltede sidekæder i ekstrudering/sfæronisering af farmaceutiske pellets
CN103705485A (zh) 一种用于治疗骨髓增生异常综合症的组合物及其制备方法
HRP20200037T4 (hr) TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
AR062509A1 (es) Proceso para preparar comprimidos de dihidrocloruro de pramipexol
Sood et al. Understanding pharmaceutical polymorphic transformations I: Influence of process variables and storage conditions
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
Dong et al. Clay as a matrix former for spray drying of drug nanosuspensions
WO2008049633A8 (en) Spray-freeze-drying process for the preparation of pellets comprising percolation drying
AR066000A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de pramipexol
Li et al. The fabrication, drug loading, and release behavior of porous mannitol
Manukonda et al. Solid dispersions-an approach to enhance the dissolution rate of Clopidogrel bisulphate
Mathavan et al. Morphological, stability, and hypoglycemic effects of new Gliclazide-bile acid microcapsules for Type 1 diabetes treatment: the microencapsulation of anti-diabetics using a microcapsule-stabilizing bile acid
AR062626A1 (es) Comprimidos de polimero de poliestireno sulfonato, su preparacion y uso
WO2017170763A1 (ja) 崩壊錠及びその製造方法

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2208 DE 30/04/2013.